Literature DB >> 10880769

The identification of novel therapeutic targets for the treatment of malignant brain tumors.

R A Kroes1, A Jastrow, M G McLone, H Yamamoto, P Colley, D S Kersey, V W Yong, E Mkrdichian, L Cerullo, J Leestma, J R Moskal.   

Abstract

A two-step strategy was developed consisting of differential display reverse transcriptase polymerase chain reaction (DDRT-PCR) with cultured normal human fetal astrocytes and U-373MG glioma cells followed by reverse Northern analysis of normal brain and primary tumor tissues. hu-dek, alpha-NAC, ribosomal proteins L7a and L35a, and five novel genes were identified. Since none of these genes has been previously shown to be associated with malignant brain tumor formation, this approach may be useful to identify novel targets for the diagnosis and treatment of brain tumors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10880769     DOI: 10.1016/s0304-3835(00)00462-6

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  46 in total

1.  Differential display: a critical analysis.

Authors:  Dana R Crawford; John C Kochheiser; Gary P Schools; Sharon L Salmon; Kelvin J A Davies
Journal:  Gene Expr       Date:  2002

2.  Crystal structures of NAC domains of human nascent polypeptide-associated complex (NAC) and its αNAC subunit.

Authors:  Lanfeng Wang; Wenchi Zhang; Lu Wang; Xuejun C Zhang; Xuemei Li; Zihe Rao
Journal:  Protein Cell       Date:  2010-05-08       Impact factor: 14.870

Review 3.  Control of tumorigenesis and chemoresistance by the DEK oncogene.

Authors:  Erica Riveiro-Falkenbach; María S Soengas
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

4.  NACA as a potential cellular target of hepatitis B virus preS1 protein.

Authors:  Dan Li; Xiao Zhong Wang; Jian Ding; Jie-Ping Yu
Journal:  Dig Dis Sci       Date:  2005-06       Impact factor: 3.199

5.  The DEK nuclear autoantigen is a secreted chemotactic factor.

Authors:  Nirit Mor-Vaknin; Antonello Punturieri; Kajal Sitwala; Neil Faulkner; Maureen Legendre; Michael S Khodadoust; Ferdinand Kappes; Jeffrey H Ruth; Alisa Koch; David Glass; Lilli Petruzzelli; Barbara S Adams; David M Markovitz
Journal:  Mol Cell Biol       Date:  2006-10-09       Impact factor: 4.272

6.  DEK in the synovium of patients with juvenile idiopathic arthritis: characterization of DEK antibodies and posttranslational modification of the DEK autoantigen.

Authors:  Nirit Mor-Vaknin; Ferdinand Kappes; Amalie E Dick; Maureen Legendre; Catalina Damoc; Seagal Teitz-Tennenbaum; Roland Kwok; Elisa Ferrando-May; Barbara S Adams; David M Markovitz
Journal:  Arthritis Rheum       Date:  2011-02

7.  Insights into gene expression changes impacting B-cell transformation: cross-species microarray analysis of bovine leukemia virus tax-responsive genes in ovine B cells.

Authors:  Pavel Klener; Maud Szynal; Yvette Cleuter; Makram Merimi; Hugues Duvillier; Françoise Lallemand; Claude Bagnis; Philip Griebel; Christos Sotiriou; Arsène Burny; Philippe Martiat; Anne Van den Broeke
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

8.  Differential expression of ribosomal proteins in a human metastasis model identified by coupling 2-D liquid chromatography and mass spectrometry.

Authors:  Paweena Kreunin; Chul Yoo; Virginia Urquidi; David M Lubman; Steve Goodison
Journal:  Cancer Genomics Proteomics       Date:  2007 Sep-Oct       Impact factor: 4.069

9.  The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.

Authors:  J Martinez-Useros; I Moreno; M J Fernandez-Aceñero; M Rodriguez-Remirez; A Borrero-Palacios; A Cebrian; T Gomez Del Pulgar; L Del Puerto-Nevado; W Li; A Puime-Otin; N Perez; M S Soengas; J Garcia-Foncillas
Journal:  BMC Cancer       Date:  2018-02-06       Impact factor: 4.430

10.  Characterizing the role of PCDH9 in the regulation of glioma cell apoptosis and invasion.

Authors:  Chunlin Wang; Bangbao Tao; Shiting Li; Bing Li; Xiaoqiang Wang; Guohan Hu; Weiqing Li; Yuhong Yu; Yicheng Lu; Jiachuan Liu
Journal:  J Mol Neurosci       Date:  2013-11-09       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.